
Disclosure of Value Transfers

Methodological Note

Country	Finland
Entity Name	Fresenius Kabi Ab, sivuliike Suomessa Filial i Finland
Legal Basis for Disclosure	Medicines for Europe Code of Conduct 2020, published February 2021
Reporting Period	1.1.2025 – 31.12.2025
Currency of disclosed values	All values are disclosed in <input checked="" type="checkbox"/> EUR <input type="checkbox"/> [local currency, if required]
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to prescription-only medicines for human use.
Value identification and Recognition	All values disclosed are based on value transfers actually made the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period.
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed for	All values are disclosed for <input type="checkbox"/> Recipients which have been engaged by entity <input checked="" type="checkbox"/> Recipients which have their residence in the country (e.g. EFPIA and Medicines for Europe)
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
Disclosure location:	https://www.fresenius-kabi.com/fi/resurssikeskus

Disclosure of Value Transfers

Value category: “Meetings, educational support and site visits of HCPs”	<p>The company discloses value transfers in this category as per Option 2 of the MfE Transparency Requirements:</p> <p>Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:</p> <ul style="list-style-type: none"> • Sponsorship for attending a third party organised congress (as per section 6.1): <ul style="list-style-type: none"> - name of congress, - aggregated amount spent for the congress, including the - number of Healthcare Professionals financially supported to attend • Site visits (as per section 6.3): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend. • Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	<p>For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.</p> <p>Fees paid in connection with research & development activities or market research have not been disclosed.</p>
